EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer

Liang Zheng, Fang Hu, Lin Huang, Jun Lu, Xiaohua Yang, Jianlin Xu, Shuyuan Wang, Yinchen Shen, Runbo Zhong, Tianqing Chu, Wei Zhang, Ying Li und 5 weitere

Journal for ImmunoTherapy of Cancer · 2024-04 · 12 (4) · e008190

DOI: 10.1136/jitc-2023-008190 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 18.04.2024. Verfasst von Liang Zheng und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School Of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shanghai Innovative Medical Device Application Demonstration Project 2023, Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Combining immune checkpoint inhibitors (ICIs) with chemotherapy has become a standard treatment for patients with non-small cell lung cancer (NSCLC) lacking driver gene mutations. Reliable biomarkers are essential for predicting treatment outcomes. Emerging evidence from various cancers suggests that early assessment of serum metabolites could serve as valuable biomarkers for predicting outcomes. This study aims to identify metabolites linked to treatment outcomes in patients with advanced NSCLC undergoing first-line or second-line therapy with programmed cell death 1 (PD-1) inhibitors plus chemotherapy.

Method

200 patients with advanced NSCLC receiving either first-line or second-line PD-1 inhibitor plus chemotherapy, and 50 patients undergoing first-line chemotherapy were enrolled in this study. The 200 patients receiving combination therapy were divided into a Discovery set (n=50) and a Validation set (n=150). These sets were further categorized into respond and non-respond groups based on progression-free survival PFS criteria (PFS≥12 and PFS1 and p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansB7-H1 AntigenBiomarkersImmune Checkpoint InhibitorsMetabolomicsAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

biomarkers, tumorimmunohistochemistrymetabolic networks and pathwaysnon-small cell lung cancer

Substanzen

B7-H1 AntigenBiomarkersImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School Of Medicine, Shanghai, China.
  • Department of Thoracic Medical Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Zhejiang, China.
  • Hangzhou Institute of Medicine (HlM), Chinese Academy of Sciences, Zhejiang, China.
  • Department of Clinical Laboratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School Of Medicine, Shanghai, China.
  • Shanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School Of Medicine, Shanghai, China.
  • Central Laboratory, Shanghai Chest Hospital, Shanghai Jiao Tong University School Of Medicine, Shanghai, China.

ORCID-Profile: Baohui Han, Xueyan Zhang

Förderung

  • Shanghai Innovative Medical Device Application Demonstration Project 2023
  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China
  • Shanghai Chest Hospital

Zitieren

APA

Zheng, L., Hu, F., Huang, L., Lu, J., Yang, X., Xu, J., Wang, S., Shen, Y., Zhong, R., Chu, T., Zhang, W., Li, Y., Zheng, X., Han, B., Zhong, H., Nie, W., & Zhang, X. (2024). Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer. Journal for ImmunoTherapy of Cancer, 12(4), e008190. https://doi.org/10.1136/jitc-2023-008190

Vancouver

Zheng L, Hu F, Huang L, Lu J, Yang X, Xu J, et al. Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer. Journal for ImmunoTherapy of Cancer. 2024;12(4):e008190. doi:10.1136/jitc-2023-008190

BibTeX
@article{Zheng2024,
  author = {Zheng, Liang and Hu, Fang and Huang, Lin and Lu, Jun and Yang, Xiaohua and Xu, Jianlin and Wang, Shuyuan and Shen, Yinchen and Zhong, Runbo and Chu, Tianqing and Zhang, Wei and Li, Ying and Zheng, Xiaoxuan and Han, Baohui and Zhong, Hua and Nie, Wei and Zhang, Xueyan},
  title = {Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  volume = {12},
  number = {4},
  pages = {e008190},
  doi = {10.1136/jitc-2023-008190}
}
Kostenlos starten →